Themis MedicareNSE:THEMISMED -0.44%78 ROE % is 8.92% as of Mar. 2026, which is 27% below its 10-year median of 12.18. GuruFocus rates NSE:THEMISMED with a GF Score™ of 78/100 and a GF Value™ of ₹149.24 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 933 Drug Manufacturers companies, Themis Medicare ranks worse than 67.63% on this metric.
The historical rank and industry rank for Themis Medicare's ROE % or its related term are showing as below:
NSE:THEMISMED'
s ROE % Range Over the Past 10 Years
Min: -6.57 Med: 12.18 Max: 28.81
Current: 0.29
During the past 13 years, Themis Medicare's highest ROE % was 28.81%. The lowest was -6.57%. And the median was 12.18%.
NSE:THEMISMED's ROE % is ranked worse than 67.63% of 933
companies
in the Drug Manufacturers industry
Industry Median: 6
vs NSE:THEMISMED: 0.29
Themis Medicare (NSE:THEMISMED) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Themis Medicare ROE % Related Terms
Themis Medicare ROE % Historical Data
* Premium members only.
The historical data trend for Themis Medicare's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Themis Medicare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Themis Medicare ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Themis Medicare's ROE % distribution charts can be found below:
* The bar in red indicates where Themis Medicare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Themis Medicare (NSE:THEMISMED) has a ROE % of 8.92% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Themis Medicare and its competitors. This is 27% below median its historical median of 12.18. According to the industry distribution chart, Themis Medicare ranks #631 out of 933 companies in the Drug Manufacturers industry, placing it in the top 67.6%.
Is Themis Medicare's ROE % too high?
Themis Medicare's current ROE % of 8.92% is 27% below median its 10-year median of 12.18. The Drug Manufacturers industry median ROE % is 6.00. Themis Medicare's value of 8.92% is 48.7% above this industry median. Based on the distribution chart, Themis Medicare ranks #631 out of 933 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Themis Medicare has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Themis Medicare's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Themis Medicare ranks #631 out of 933 companies for ROE %. This places Themis Medicare in the lower half of its industry. The industry median ROE % is 6.00. Themis Medicare's value of 8.92% is 48.7% above this benchmark. While the company's 10-year median is 12.18 vs. the industry median of 6.00, Themis Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Themis Medicare's current ROE % of 8.92% is 48.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Themis Medicare and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Themis Medicare's current ROE % is 8.92%, which is 27% below median its own 10-year median of 12.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Themis Medicare stock overvalued right now?
Based on GuruFocus' analysis, Themis Medicare (NSE:THEMISMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹149.24, compared to a current price of ₹118.59 — trading 20.5% below its estimated fair value. The current ROE % is 8.92%, which is 27% below median its 10-year median of 12.18 and 48.7% above the Drug Manufacturers industry median of 6.00. Themis Medicare's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Themis Medicare (NSE:THEMISMED), the current ROE % is 8.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Themis Medicare (NSE:THEMISMED) Overvalued in 2026?
Based on GuruFocus' analysis, Themis Medicare stock appears to be undervalued.
The current stock price of ₹118.59 is trading 20.5% below its estimated GF Value™ of ₹149.24.
GuruFocus considers Themis Medicare to be Modestly Undervalued.
Key valuation signals for NSE:THEMISMED:
ROE %: 8.92% (27% below median its 10-year median of 12.18)
GF Value™: ₹149.24 vs. price of ₹118.59 (20.5% below fair value)
Industry Position: 48.7% above the Drug Manufacturers median (#631 of 933)
No single metric tells the full story. See the NSE:THEMISMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Themis Medicare Ltd is an Indian based company engaged in the manufacturing and marketing of pharmaceutical products. The Company operates only in one business segment which is Pharmaceuticals. Geographically, it derives a majority of revenue from India and also has a presence in the international market. Its product categories include Anti Malarial, CCD products, Nutritional Gummies, and Candy and Other Products such as OD-LM, Dexem, Medzol and Tazowin.
78GF Score
Get the complete analysis for NSE:THEMISMED
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THEMISMED has been successfully added to your 
